Supra seasonal universal influenza vaccine inactivated - GlaxoSmithKline

Drug Profile

Supra seasonal universal influenza vaccine inactivated - GlaxoSmithKline

Alternative Names: GSK3816302A; SUIVs

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 14 Sep 2017 Preclinical trials in Influenza virus infections in United Kingdom (IM)
  • 14 Sep 2017 GlaxoSmithKline plans a phase I trial in Healthy volunteers (NCT03275389)
  • 08 Sep 2017 Phase-I clinical trials in Influenza virus infections (In volunteers) in USA (IM) (NCT03275389)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top